According to The Fly, roth Capital analyst Jotin Marango maintained a Buy rating on Aptose Biosciences (APTO) today. The company’s shares opened today at $2.21.
Marango commented:
“We remain bullish on the value of the cluster-specific kinase inhibitor CG’806, as it heads into an IND in 1Q19. We believe that the upcoming Phase 1 program covering both myeloid and lymphoid malignancy will cast an appropriately wide net, and are encouraged by multiple potential target disease subpopulations emerging from the preclinical data.”
According to TipRanks.com, Marango ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -14.0% and a 23.2% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Stemline Therapeutics Inc, and Cyclacel Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aptose Biosciences with a $6.75 average price target, representing a 205.4% upside. In a report issued on December 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.50 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.55 and a one-year low of $1.68. Currently, Aptose Biosciences has an average volume of 213.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG’806 a non-covalent small molecule therapeutic agent.
